Immune to Cancer: The CRI Blog
-
AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…
-
AACR19 Day 5 Update: Bispecific Antibodies, the Importance of “Helper” T Cells, and the Lloyd J. Old Award Lecture
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to…
-
AACR19 Day 4 Update: The Microbiome, Immunotherapy Biomarkers, and New Immune Targets
Day 4 of AACR19 explored the microbiome and its impact on cancer treatment, revealed insights into immunotherapy…
-
AACR19 Day 3 Update: CAR T Cells, Vaccines, and Hope Against Pancreatic Cancer
In addition to advances involving CAR T cell therapy and vaccines, a CRI-funded trial revealed the promise…
-
CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…
-
Personalizing Cancer Treatment
Dr. Patrick Hwu discusses the current state of cancer care and how recent advances are enabling doctors…
-
Transforming Experience into Advocacy
Judy Perkins discusses her experience receiving immunotherapy for metastatic stage 4 breast cancer and insights she shared…
-
AACR19 Preview: CRI Scientists Showcase the Future of Immunotherapy
The 2019 AACR annual meeting kicks off March 29 in Atlanta and will feature the work of…
-
Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer
Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.